semaglutide gastrointestinal obstruction class action in louisiana Ozempic Lawsuit [2026 Update] FDA Ileus Semaglutide ozempic wegovy
Description
Intramuscular injection bypasses the drug's pharmacokinetic design, potentially reducing bioavailability and increasing systemic exposure variability
![semaglutide gastrointestinal obstruction class action in louisiana Ozempic Lawsuit [2026 Update] FDA Ileus Semaglutide ozempic wegovy](https://www.gastroendonews.com/cover/2026/GEN0726cover_150.jpg)
The nationwide number of semaglutide overdoses this year is more than double the 1,447 reported in 2022, which was more than double the 607 semaglutide overdoses reported in 2021
![semaglutide gastrointestinal obstruction class action in louisiana Ozempic Lawsuit [2026 Update] FDA Ileus Semaglutide ozempic wegovy](https://www.atraxialaw.com/uploads/glps-legal-events.jpg?w=550&q=70&zc=1)
A new genetic study suggests that higher levels of the hormone dehydroepiandrosterone sulfate (DHEA-s) are associated with a shorter lifespan in men, but show no significant effect on the lifespan of women
![semaglutide gastrointestinal obstruction class action in louisiana Ozempic Lawsuit [2026 Update] FDA Ileus Semaglutide ozempic wegovy](https://www.bursor.com/wp-content/uploads/iStock-2155518034-scaled-e1741638529576.jpg)
Research shows that pairing these medications may produce additive effects on glucose control and appetite suppression, though individual responses vary based on genetics and metabolism
![semaglutide gastrointestinal obstruction class action in louisiana Ozempic Lawsuit [2026 Update] FDA Ileus Semaglutide ozempic wegovy](https://healthogenics.com/cdn/shop/files/Semaglutide_Vial_5c04ccb5-14cf-4800-ae49-14166ffa7a15.png)
Those with resistant hypertension despite three or more medications may also see benefit, though individual response remains unpredictable
![semaglutide gastrointestinal obstruction class action in louisiana Ozempic Lawsuit [2026 Update] FDA Ileus Semaglutide ozempic wegovy](https://www.elglaw.com/uploads/is-ileus-caused-by-semaglutide-treatable.jpg)
Evidence-based obesity treatments target appetite and metabolic pathways with strong clinical data